Welcome back to the MIT SRP Blog!
We have quite a variety of scientists and research projects in our program, so over time you’ll have the chance to hear many different perspectives in this blog. Since I have the privilege of writing the first few posts, I’m going to begin with my specialty, the development of cancer. I want to start this conversation with the basics: where does cancer come from?
This is a HUGE question with lots of facets, more than I can address in one post, so let’s take it one step at a time.
Cancer arises from normal cells misbehaving (proliferating when they’re not supposed to, migrating where they’re not supposed to, surviving when they’re not supposed to, etc.). Such misbehavior can be caused by alterations to the genetic instruction manual that provides the basis of all cellular activity. In fact, many of us in the field consider cancer to be a disease of the genome.
Cells read the sequences of nucleotides in their DNA as instructions for assembling the proteins that perform cellular functions (generally, each DNA sequence that encodes a protein is called a gene). Every cell has a complete copy of the genetic code, but different cell types use different sets of genes to accomplish their particular roles. Broadly speaking, if a gene’s sequence is altered (called a mutation), then the protein may be assembled incorrectly, and that particular function of the cell won’t be executed properly.
Cancer arises when cells accumulate multiple mutations that enable escape from normal behavior. The most common carcinogenic mutations include inactivation of genes that keep behaviors in check (e.g., moderating cell division, regulating migration, inducing programmed death) or improper activation of genes that enable behaviors (e.g., enhancing proliferation, activating migration, resisting programmed death). Mutations enable cancer cells to evolve, continually altering their behavior to enhance growth, escape normal physiological confines, and resist cell death. (By the way, this accelerated evolution is what makes cancer so difficult to treat, since cancer cells are constantly altering themselves to resist chemotherapeutics, but that’s a story for another time.)
Mutations become more likely when the cell’s DNA has undergone damage, such as alterations to the nucleotide structure. If the nucleotide looks wrong, the cell will have difficulty interpreting it properly. (In our book analogy, if the top bar on a capital T is gone, you might incorrectly transcribe it as a lowercase l. Similarly, if the cell doesn’t recognize G as G due to a change in its structure, it won’t know to pair it with C.)
PAHs create large adducts on DNA, and it’s easy to see how a giant lesion could obscure the identity of the nucleotide or block cellular machinery from copying the DNA altogether.
Two of our research projects are specifically aimed at studying the genetic impacts of exposures to NDMA and PAHs. Project 3 will determine the unique patterns of mutations that occur when animals are exposed to these chemicals, and Project 4 will study how the inability to repair DNA damage impacts cancer susceptibility.
In our next entry, we’ll dive into how DNA repair pathways help protect against mutations and discuss why some people are more likely to get cancer than others.